These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38501656)
41. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice. Peron A; Au KS; Northrup H Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):281-290. PubMed ID: 30255984 [TBL] [Abstract][Full Text] [Related]
42. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC -associated Renal Cell Carcinoma. Argani P; Matoso A; Pallavajjalla A; Haley L; Tseh-Lin M; Ng J; Chow CW; Lotan T; Mehra R Am J Surg Pathol; 2022 Nov; 46(11):1554-1561. PubMed ID: 35941720 [TBL] [Abstract][Full Text] [Related]
43. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901 [TBL] [Abstract][Full Text] [Related]
44. Comprehensive Genetic Analysis Results of TSC1/TSC2 Genes in Patients with Clinical Suspicion of Tuberous Sclerosis Complex and Definition of 3 Novel Variants. Demir S; Yalçıntepe S; Atlı E; Yalçın Y; İkbal Atlı E; Eker D; Karal Y; Gürkan H Balkan Med J; 2021 Nov; 38(6):341-347. PubMed ID: 34860161 [TBL] [Abstract][Full Text] [Related]
45. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109 [TBL] [Abstract][Full Text] [Related]
46. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760 [TBL] [Abstract][Full Text] [Related]
47. The association of neurodevelopmental abnormalities, congenital heart and renal defects in a tuberous sclerosis complex patient cohort. Robinson J; Uzun O; Loh NR; Harris IR; Woolley TE; Harwood AJ; Gardner JF; Syed YA BMC Med; 2022 Apr; 20(1):123. PubMed ID: 35440050 [TBL] [Abstract][Full Text] [Related]
48. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex. Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214 [TBL] [Abstract][Full Text] [Related]
49. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex. Samuels JA Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901 [TBL] [Abstract][Full Text] [Related]
50. Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis. Suspitsin EN; Yanus GA; Dorofeeva MY; Ledashcheva TA; Nikitina NV; Buyanova GV; Saifullina EV; Sokolenko AP; Imyanitov EN J Hum Genet; 2018 May; 63(5):597-604. PubMed ID: 29476190 [TBL] [Abstract][Full Text] [Related]
51. Sporadic hemangioblastoma of the kidney with PAX2 and focal CD10 expression: report of a case. Jiang JG; Rao Q; Xia QY; Tu P; Lu ZF; Shen Q; Zhang RS; Yu B; Zhou XJ; Shi SS; Shi QL Int J Clin Exp Pathol; 2013; 6(9):1953-6. PubMed ID: 24040464 [TBL] [Abstract][Full Text] [Related]
52. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Tyburczy ME; Wang JA; Li S; Thangapazham R; Chekaluk Y; Moss J; Kwiatkowski DJ; Darling TN Hum Mol Genet; 2014 Apr; 23(8):2023-9. PubMed ID: 24271014 [TBL] [Abstract][Full Text] [Related]
53. A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway. Fu J; Liang P; Zheng Y; Xu C; Xiong F; Yang F Gene; 2024 May; 909():148312. PubMed ID: 38412945 [TBL] [Abstract][Full Text] [Related]
54. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity. Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634 [TBL] [Abstract][Full Text] [Related]
55. PTEN Expression, Not Mutation Status in Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302 [TBL] [Abstract][Full Text] [Related]
56. Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified. Camposano SE; Greenberg E; Kwiatkowski DJ; Thiele EA Ann Hum Genet; 2009 Mar; 73(2):141-6. PubMed ID: 19133941 [TBL] [Abstract][Full Text] [Related]
58. Renal disease in tuberous sclerosis complex: pathogenesis and therapy. Lam HC; Siroky BJ; Henske EP Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611 [TBL] [Abstract][Full Text] [Related]
60. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. Hino O; Kobayashi T Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]